Artificial Intelligence Generated Molecules Entering Trials: Provenance, Novelty and Attribution
DOI:
https://doi.org/10.5281/zenodo.22649409Keywords:
Artificial Intelligence Generated Molecules Entering Trials;, Translational medicine; Evidence synthesis, Clinical implementation; Health services researchAbstract
Artificial Intelligence Generated Molecules Entering Trials is an area of active development in translational medicine, with
evidence that has accumulated unevenly across its component questions. We review the current evidence base for artificial
intelligence generated molecules entering trials, spanning analytical, clinical, implementation, governance, and economic
dimensions, focusing on where practice has converged and where it continues to vary, and set out the practical considerations
relevant to a service considering its adoption. We conclude that selective, context-specific use is best supported by the evidence
currently available, rather than uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.1007/s10916-024-02104-9
Brankovic K, Kowalczyk B, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.3389/fdgth.2026.1896184
Castellani R, Ristic C, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3390/diagnostics15162117
Dumitrescu A, Andric D, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.4103/jrpp.jrpp_20_65
Eriksdottir B, Brankovic E, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.3389/fdgth.2026.1763884
Farkas I, Ionescu F, et al. "Artificial Intelligence Generated Molecules Entering Trials: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.2196/48297
Grabowski P, Petrescu G, et al. "Artificial Intelligence Generated Molecules Entering Trials: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1007/s00330-025-12031-z
Hendriksen W, Wojcik H, et al. "Artificial Intelligence Generated Molecules Entering Trials: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.3389/fdgth.2026.1699005
Ionescu F, Foscarini I, et al. "Artificial Intelligence Generated Molecules Entering Trials: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.3389/fdgth.2026.1834800
Jankowiak G, Grabowski J, et al. "Artificial Intelligence Generated Molecules Entering Trials: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.2196/69678
Kowalczyk N, Novotna K, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.7759/cureus.46454
Lindqvist U, Urbanek L, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.1016/j.ssci.2025.107028
Marchetti D, Doncheva M, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.2196/48633
Novotna E, Eriksdottir N, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1371/journal.pone.0305949
Ostrowski L, Lindqvist O, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1371/journal.pdig.0000514
Petrescu S, Szabo P, et al. "Artificial Intelligence Generated Molecules Entering Trials: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.17219/acem/208596
Quintero B, Balogh Q, et al. "Artificial Intelligence Generated Molecules Entering Trials: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.7759/cureus.104086
Ristic C, Castellani R, et al. "Artificial Intelligence Generated Molecules Entering Trials: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1038/s41746-023-00852-5
Szabo J, Jankowiak S, et al. "Artificial Intelligence Generated Molecules Entering Trials: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1016/j.mayocpiqo.2022.09.004
Tarasov Q, Quintero T, et al. "Artificial Intelligence Generated Molecules Entering Trials: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.1177/08404704241291226
Urbanek Z, Zielinski U, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1093/medlaw/fwad013
Vasquez A, Alvez V, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.2196/89834
Wojcik H, Hendriksen W, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.1007/s10916-024-02104-9
Zielinski O, Ostrowski Z, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.3389/fdgth.2026.1896184
Andric V, Vasquez A, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3390/diagnostics15162117
Balogh E, Emmerich B, et al. "Artificial Intelligence Generated Molecules Entering Trials: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.4103/jrpp.jrpp_20_65
Chiriac F, Farkas C, et al. "Artificial Intelligence Generated Molecules Entering Trials: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.3389/fdgth.2026.1763884
Doncheva M, Marchetti D, et al. "Artificial Intelligence Generated Molecules Entering Trials: a validation study". Trials 22(2017): 377-383. DOI: 10.2196/48297
Emmerich T, Tarasov E, et al. "Artificial Intelligence Generated Molecules Entering Trials: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1007/s00330-025-12031-z
Foscarini C, Chiriac F, et al. "Artificial Intelligence Generated Molecules Entering Trials: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.3389/fdgth.2026.1699005
Alvez D, Dumitrescu A, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.3389/fdgth.2026.1834800
Brankovic K, Kowalczyk B, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.2196/69678
Castellani R, Ristic C, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.7759/cureus.46454
Dumitrescu A, Andric D, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.1016/j.ssci.2025.107028
Eriksdottir B, Brankovic E, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.2196/48633
Farkas I, Ionescu F, et al. "Artificial Intelligence Generated Molecules Entering Trials: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1371/journal.pone.0305949
Grabowski P, Petrescu G, et al. "Artificial Intelligence Generated Molecules Entering Trials: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1371/journal.pdig.0000514
Hendriksen W, Wojcik H, et al. "Artificial Intelligence Generated Molecules Entering Trials: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.17219/acem/208596
Ionescu F, Foscarini I, et al. "Artificial Intelligence Generated Molecules Entering Trials: a scoping review". JAMA 44(2020): 498-506. DOI: 10.7759/cureus.104086
Jankowiak G, Grabowski J, et al. "Artificial Intelligence Generated Molecules Entering Trials: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1038/s41746-023-00852-5
Kowalczyk N, Novotna K, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1016/j.mayocpiqo.2022.09.004
Lindqvist U, Urbanek L, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.1177/08404704241291226
Marchetti D, Doncheva M, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1093/medlaw/fwad013
Novotna E, Eriksdottir N, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.2196/89834
Ostrowski L, Lindqvist O, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.1007/s10916-024-02104-9
Petrescu S, Szabo P, et al. "Artificial Intelligence Generated Molecules Entering Trials: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.3389/fdgth.2026.1896184
Quintero B, Balogh Q, et al. "Artificial Intelligence Generated Molecules Entering Trials: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3390/diagnostics15162117
Ristic C, Castellani R, et al. "Artificial Intelligence Generated Molecules Entering Trials: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.4103/jrpp.jrpp_20_65
Szabo J, Jankowiak S, et al. "Artificial Intelligence Generated Molecules Entering Trials: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.3389/fdgth.2026.1763884
Tarasov Q, Quintero T, et al. "Artificial Intelligence Generated Molecules Entering Trials: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.2196/48297
Urbanek Z, Zielinski U, et al. "Artificial Intelligence Generated Molecules Entering Trials: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1007/s00330-025-12031-z
Vasquez A, Alvez V, et al. "Artificial Intelligence Generated Molecules Entering Trials: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.3389/fdgth.2026.1699005
Wojcik H, Hendriksen W, et al. "Artificial Intelligence Generated Molecules Entering Trials: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.3389/fdgth.2026.1834800
Zielinski O, Ostrowski Z, et al. "Artificial Intelligence Generated Molecules Entering Trials: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.2196/69678
Andric V, Vasquez A, et al. "Artificial Intelligence Generated Molecules Entering Trials: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.7759/cureus.46454
